IL-33 induces a hyporesponsive phenotype in human and mouse mast cells

Journal of Immunology

Volumn 190, Issue 2, 2013, Pages 531-538

  Jung, Mi Yeon ^a   Smrž, Daniel ^a   Desai, Avanti ^a   Bandara, Geethani ^a   Ito, Tomonobu ^a   Iwaki, Shoko ^b   Kang, Jeong Han ^c   Andrade, Marcus V ^d   Hilderbrand, Susana C ^e   Brown, Jared M ^e   Beaven, Michael A ^b   Metcalfe, Dean D ^a   Gilfillan, Alasdair M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^e EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CALCIUM ION; FC EPSILON RI; HEMATOPOIETIC CELL KINASE; IMMUNOGLOBULIN E RECEPTOR; INTERLEUKIN 33; INTERLEUKIN RECEPTOR; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHOLIPASE C GAMMA1; PROTEIN ST2; UNCLASSIFIED DRUG;

ACTIN POLYMERIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGENIC MODULATION; ARTICLE; CALCIUM MOBILIZATION; CALCIUM SIGNALING; CELL ACTIVATION; CELL KINETICS; CELL MANIPULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOSKELETON; DEPOLYMERIZATION; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LONG TERM EXPOSURE; MAST CELL; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACTINS; ANIMALS; BONE MARROW CELLS; HUMANS; IMMUNOSUPPRESSION; INTERLEUKINS; MAST CELLS; MICE; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; PHENOTYPE; PHOSPHOLIPASE C GAMMA; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS C-HCK; RECEPTORS, INTERLEUKIN;

EID: 84872187708     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201576     Document Type: Article

References (37)

1. Kalesnikoff, J., and S. J. Galli. 2008. New developments in mast cell biology. Nat. Immunol. 9: 1215-1223.
2. Mekori, Y. A., and D. D. Metcalfe. 2000. Mast cells in innate immunity. Immunol. Rev. 173: 131-140.
3. Kraft, S., and J. P. Kinet. 2007. New developments in FcεRI regulation, function and inhibition. Nat. Rev. Immunol. 7: 365-378.
4. Gilfillan, A. M., and M. A. Beaven. 2011. Regulation of mast cell responses in health and disease. Crit. Rev. Immunol. 31: 475-529.
5. Liew, F. Y., N. I. Pitman, and I. B. McInnes. 2010. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 10: 103-110.
6. Hsu, C. L., C. V. Neilsen, and P. J. Bryce. 2010. IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS ONE 5: e11944.
7. Iikura, M., H. Suto, N. Kajiwara, K. Oboki, T. Ohno, Y. Okayama, H. Saito, S. J. Galli, and S. Nakae. 2007. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab. Invest. 87: 971-978.
8. Andrade, M. V., S. Iwaki, C. Ropert, R. T. Gazzinelli, J. R. Cunha-Melo, and M. A. Beaven. 2011. Amplification of cytokine production through synergistic activation of NFAT and AP-1 following stimulation of mast cells with antigen and IL-33. Eur. J. Immunol. 41: 760-772.
9. Silver, M. R., A. Margulis, N. Wood, S. J. Goldman, M. Kasaian, and D. Chaudhary. 2010. IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm. Res. 59: 207-218.
10. Allakhverdi, Z., D. E. Smith, M. R. Comeau, and G. Delespesse. 2007. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J. Immunol. 179: 2051-2054.
11. Ho, L. H., T. Ohno, K. Oboki, N. Kajiwara, H. Suto, M. Iikura, Y. Okayama, S. Akira, H. Saito, S. J. Galli, and S. Nakae. 2007. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcåRI signals. J. Leukoc. Biol. 82: 1481-1490.
12. Moulin, D., O. Donzé, D. Talabot-Ayer, F. Mézin, G. Palmer, and C. Gabay. 2007. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 40: 216-225.
13. +, and expresses aminopeptidase N (CD13). Blood 94: 2333-2342.
14. Adachi, O., T. Kawai, K. Takeda, M. Matsumoto, H. Tsutsui, M. Sakagami, K. Nakanishi, and S. Akira. 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9: 143-150.
15. Yang, D., Q. Chen, S. B. Su, P. Zhang, K. Kurosaka, R. R. Caspi, S. M. Michalek, H. F. Rosenberg, N. Zhang, and J. J. Oppenheim. 2008. Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. J. Exp. Med. 205: 79-90.
16. Kuehn, H. S., M. A. Beaven, H. T. Ma, M. S. Kim, D. D. Metcalfe, and A. M. Gilfillan. 2008. Synergistic activation of phospholipases Cγ and Cβ: a novel mechanism for PI3K-independent enhancement of FcεRI-induced mast cell mediator release. Cell. Signal. 20: 625-636.
17. 1-dependent pathway of FcεRI-mediated mast cell activation is regulated independently of phosphatidylinositol 3-kinase. J. Biol. Chem. 278: 48474-48484.
18. Qiao, H., M. V. Andrade, F. A. Lisboa, K. Morgan, and M. A. Beaven. 2006. FcεR1 and Toll-like receptors mediate synergistic signals to markedly augment production of inflammatory cytokines in murine mast cells. Blood 107: 610-618.
19. Kuehn, H. S., M. Rådinger, and A. M. Gilfillan. 2010. Measuring mast cell mediator release. Curr. Protoc. Immunol. Chapter 7: Unit 7.38.
20. Choi, O. H., J. H. Lee, T. Kassessinoff, J. R. Cunha-Melo, S. V. P. Jones, and M. A. Beaven. 1993. Antigen and carbachol mobilize calcium by similar mechanisms in a transfected mast cell line (RBL-2H3 cells) that expresses ml muscarinic receptors. J. Immunol. 151: 5586-5595.
21. Liu, F. T., J. W. Bohn, E. L. Ferry, H. Yamamoto, C. A. Molinaro, L. A. Sherman, N. R. Klinman, and D. H. Katz. 1980. Monoclonal dinitrophenyl-specific murine IgE antibody: preparation, isolation, and characterization. J. Immunol. 124: 2728-2737.
22. Tkaczyk, C., D. D. Metcalfe, and A. M. Gilfillan. 2002. Determination of protein phosphorylation in FcεRI-activated human mast cells by immunoblot analysis requires protein extraction under denaturing conditions. J. Immunol. Methods 268: 239-243.
23. Hundley, T. R., A. M. Gilfillan, C. Tkaczyk, M. V. Andrade, D. D. Metcalfe, and M. A. Beaven. 2004. Kit and FcεRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells. Blood 104: 2410-2417.
24. Ito, T., D. Smrž, M. Y. Jung, G. Bandara, A. Desai, Š. Smržová, H. S. Kuehn, M. A. Beaven, D. D. Metcalfe, and A. M. Gilfillan. 2012. Stem cell factor programs the mast cell activation phenotype. J. Immunol. 188: 5428-5437.
25. 2+ signaling with particular focus on mast cells. Crit. Rev. Immunol. 29: 155-186.
26. Gadina, M., and C. A. Jefferies. 2007. IL-33: a sheep in wolf's clothing? Sci. STKE 2007: pe31.
27. Gilfillan, A. M., and C. Tkaczyk. 2006. Integrated signalling pathways for mast-cell activation. Nat. Rev. Immunol. 6: 218-230.
28. Hong, H., J. Kitaura, W. Xiao, V. Horejsi, C. Ra, C. A. Lowell, Y. Kawakami, and T. Kawakami. 2007. The Src family kinase Hck regulates mast cell activation by suppressing an inhibitory Src family kinase Lyn. Blood 110: 2511-2519.
29. Guiet, R., R. Poincloux, J. Castandet, L. Marois, A. Labrousse, V. Le Cabec, and I. Maridonneau-Parini. 2008. Hematopoietic cell kinase (Hck) isoforms and phagocyte duties: from signaling and actin reorganization to migration and phagocytosis. Eur. J. Cell Biol. 87: 527-542.
30. Xu, D., H. R. Jiang, P. Kewin, Y. Li, R. Mu, A. R. Fraser, N. Pitman, M. Kurowska-Stolarska, A. N. McKenzie, I. B. McInnes, and F. Y. Liew. 2008. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc. Natl. Acad. Sci. USA 105: 10913-10918.
31. Smith, D. E. 2010. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin. Exp. Allergy 40: 200-208.
32. Theoharides, T. C., B. Zhang, D. Kempuraj, M. Tagen, M. Vasiadi, A. Angelidou, K. D. Alysandratos, D. Kalogeromitros, S. Asadi, N. Stavrianeas, et al. 2010. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc. Natl. Acad. Sci. USA 107: 4448-4453.
33. Pushparaj, P. N., H. K. Tay, S. C. H'ng, N. Pitman, D. Xu, A. McKenzie, F. Y. Liew, and A. J. Melendez. 2009. The cytokine interleukin-33 mediates anaphylactic shock. Proc. Natl. Acad. Sci. USA 106: 9773-9778.
34. Kuehn, H. S., M. Rådinger, J. M. Brown, K. Ali, B. Vanhaesebroeck, M. A. Beaven, D. D. Metcalfe, and A. M. Gilfillan. 2010. Btk-dependent Rac activation and actin rearrangement following FcεRI aggregation promotes enhanced chemotactic responses of mast cells. J. Cell Sci. 123: 2576-2585.
35. Saluja, R., I. Delin, G. P. Nilsson, and M. Adner. 2012. FcεR1-mediated mast cell reactivity is amplified through prolonged Toll-like receptor-ligand treatment. PLoS ONE 7: e43547.
36. Metcalfe, D. D., R. D. Peavy, and A. M. Gilfillan. 2009. Mechanisms of mast cell signaling in anaphylaxis. J. Allergy Clin. Immunol. 124: 639-646.
37. Kennedy Norton, S., B. Barnstein, J. Brenzovich, D. P. Bailey, M. Kashyap, K. Speiran, J. Ford, D. Conrad, S. Watowich, M. R. Moralle, et al. 2008. IL-10 suppresses mast cell IgE receptor expression and signaling in vitro and in vivo. J. Immunol. 180: 2848-2854.